RxDoctor Payments Data

Bianca Pope

Family · Brunswick, GANPI 1124465588

Payments from drug & device makers

$2,442in general payments, 2019–2025

Across 116 payments — averaging $21.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$469
  • Novo Nordisk$457
  • Takeda Pharmaceuticals U.S.A., Inc.$278
  • Otsuka America Pharmaceutical, Inc.$187
  • Eko Health, Inc.$150
  • Lilly USA, LLC$149
  • plus $752 from 15 others

What the payments were for

  • Speaking & faculty fees$1506%
  • Food & beverage$2,19290%
  • Education$1004%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,442 in reported general payments places this provider in the 80th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$17,061
Medicare patients
43
Services billed
276

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide25$31,431
MounjaroTirzepatide19$22,920
RybelsusSemaglutide11$12,662
Levothyroxine Sodium56$737
Atorvastatin Calcium67$728
Bupropion XlBupropion Hcl22$443
Venlafaxine Hcl ErVenlafaxine Hcl16$433
Gabapentin17$425
Omeprazole27$396
Levocetirizine Dihydrochloride16$235
Rosuvastatin Calcium27$224
Metformin Hcl ErMetformin Hcl16$212
Lisinopril28$198
Fluoxetine Hcl17$197
Losartan Potassium29$193

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$457$44,09336 claims
Lilly USA, LLCMounjaro$149$22,92019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,258 family providers in Georgia.

Other family in Brunswick

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →